Vertex Pharmaceuticals, Inc. (VRTX)
515.44
+0.88
(+0.17%)
USD |
NASDAQ |
Sep 11, 16:00
515.73
+0.29
(+0.06%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value : 124.70B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 124.70B |
| September 10, 2026 | 124.48B |
| September 09, 2026 | 126.14B |
| September 08, 2026 | 128.11B |
| September 04, 2026 | 132.47B |
| September 03, 2026 | 135.47B |
| September 02, 2026 | 135.17B |
| September 01, 2026 | 132.86B |
| August 31, 2026 | 132.07B |
| August 28, 2026 | 131.35B |
| August 27, 2026 | 132.84B |
| August 26, 2026 | 132.77B |
| August 25, 2026 | 134.18B |
| August 24, 2026 | 132.85B |
| August 21, 2026 | 132.96B |
| August 20, 2026 | 130.99B |
| August 19, 2026 | 133.98B |
| August 18, 2026 | 127.93B |
| August 17, 2026 | 124.73B |
| August 14, 2026 | 122.25B |
| August 13, 2026 | 124.95B |
| August 12, 2026 | 127.31B |
| August 11, 2026 | 128.30B |
| August 10, 2026 | 126.85B |
| August 07, 2026 | 119.79B |
| Date | Value |
|---|---|
| August 06, 2026 | 116.74B |
| August 05, 2026 | 116.95B |
| August 04, 2026 | 115.39B |
| August 03, 2026 | 113.37B |
| July 31, 2026 | 114.99B |
| July 30, 2026 | 116.15B |
| July 29, 2026 | 116.57B |
| July 28, 2026 | 118.35B |
| July 27, 2026 | 115.47B |
| July 24, 2026 | 115.05B |
| July 23, 2026 | 113.97B |
| July 22, 2026 | 113.84B |
| July 21, 2026 | 116.23B |
| July 20, 2026 | 115.85B |
| July 17, 2026 | 117.15B |
| July 16, 2026 | 117.25B |
| July 15, 2026 | 114.98B |
| July 14, 2026 | 114.79B |
| July 13, 2026 | 115.78B |
| July 10, 2026 | 117.09B |
| July 09, 2026 | 119.90B |
| July 08, 2026 | 120.39B |
| July 07, 2026 | 126.43B |
| July 06, 2026 | 128.28B |
| July 02, 2026 | 127.89B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 199.64B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Sionna Therapeutics, Inc. | 151.58M |
| Regeneron Pharmaceuticals, Inc. | 75.51B |
| Biogen, Inc. | 39.14B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.100B |
| Revenue (Quarterly) | 3.344B |
| Total Expenses (Quarterly) | 2.244B |
| EPS Diluted (Quarterly) | 4.310 |
| Gross Profit Margin (Quarterly) | 85.37% |
| Profit Margin (Quarterly) | 32.89% |
| Earnings Yield | 3.33% |
| Operating Earnings Yield | 3.80% |
| Normalized Earnings Yield | 3.426 |